ValuEngine upgraded shares of Insys Therapeutics (NASDAQ:INSY) from a sell rating to a hold rating in a report issued on Friday morning.

Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Insys Therapeutics from a hold rating to a buy rating and set a $8.50 price objective on the stock in a research note on Wednesday, October 18th. Royal Bank of Canada set a $8.00 price objective on shares of Insys Therapeutics and gave the stock a buy rating in a research note on Friday, October 27th. Jefferies Group lowered their price objective on shares of Insys Therapeutics from $14.00 to $11.00 and set a buy rating on the stock in a research note on Friday, November 3rd. Finally, Oppenheimer restated a hold rating on shares of Insys Therapeutics in a research note on Sunday, November 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $9.38.

Insys Therapeutics (NASDAQ INSY) opened at $9.62 on Friday. Insys Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.02. The company has a market cap of $631.99, a P/E ratio of -3.77 and a beta of 0.81.

Several institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN grew its stake in shares of Insys Therapeutics by 0.5% in the second quarter. Wells Fargo & Company MN now owns 27,667 shares of the specialty pharmaceutical company’s stock worth $350,000 after acquiring an additional 126 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Insys Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 79,943 shares of the specialty pharmaceutical company’s stock worth $1,012,000 after acquiring an additional 475 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Insys Therapeutics by 4.5% in the second quarter. The Manufacturers Life Insurance Company now owns 21,576 shares of the specialty pharmaceutical company’s stock worth $274,000 after acquiring an additional 938 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in shares of Insys Therapeutics by 4.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 37,885 shares of the specialty pharmaceutical company’s stock worth $479,000 after acquiring an additional 1,541 shares during the last quarter. Finally, Teachers Advisors LLC boosted its stake in Insys Therapeutics by 3.7% during the second quarter. Teachers Advisors LLC now owns 45,016 shares of the specialty pharmaceutical company’s stock worth $569,000 after buying an additional 1,604 shares in the last quarter. Institutional investors and hedge funds own 25.60% of the company’s stock.

WARNING: “Insys Therapeutics (INSY) Upgraded to Hold at ValuEngine” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://theolympiareport.com/2018/01/02/insys-therapeutics-insy-upgraded-to-hold-at-valuengine.html.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.